Chemical Reengineering of Antibodies to Enhance/Improve their Function
Kleo’s monoclonal antibody therapy enhancer (MATE™) platform enables site-directed, chemical conjugation to off-the-shelf therapeutic monoclonal antibodies (mAbs), or therapeutic intravenous immunoglobulin (IVIG) pooled from healthy donors.
Our novel and proprietary MATE platform allows for the chemical engineering of existing antibodies without the need to create new DNA vectors or master cell lines. Previous conjugation technologies either (1) lack site-directed conjugation specificity by binding indiscriminately to available amino acid residues (ie. lysine) or (2) or required genetic engineering to create conjugation tags.
Kleo’s ‘dump-and-stir’ approach is highly efficient and amenable to multiple types of conjugates:
- Antibody fragments (Fabs or scFv) to rapidly create bispecific mAbs (ie two checkpoint inhibitors or two tumor targets)
- Attachment of CD3-targeting binder to a therapeutic monoclonal antibody for novel t-cell engagers
CHARACTERISTICS OF MATE ANTIBODIES:
- Retain epitope binding of the parental mAb
- Retain FcRn binding to ensure the stability of parental mAb
- Retain CD16a binding on immune effector cells to retain immune-mediated mechanisms of action
- In vivo efficacy and stability demonstrated
Kleo is seeking additional partners with the goal of (1) adding additional functionality to marketed mAbs (2) rapidly creating novel bispecific combinations including bispecific t-cell engagers (3) exploring mAb-mAb conjugates